Trial Profile
An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 19 Sep 2019 Planned End Date changed from 11 Sep 2019 to 30 Sep 2019.
- 19 Sep 2019 Planned primary completion date changed from 11 Sep 2019 to 30 Sep 2019.